PNC Financial Services Group’s Tvardi Therapeutics TVRD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.65K Buy
519
+225
+77% +$882 ﹤0.01% 4639
2025
Q4
$1.26K Buy
294
+246
+513% +$2.21K ﹤0.01% 4639
2025
Q3
$1.87K Buy
+48
New +$1.37K ﹤0.01% 4514
2024
Q1
Sell
-2
Closed -$52 4840
2023
Q4
$52 Buy
+2
New +$83 ﹤0.01% 4561
2023
Q2
Sell
-34
Closed -$5.93K 4852
2023
Q1
$5.93K Sell
34
-62
-65% -$20.8K ﹤0.01% 3980
2022
Q4
$36.9K Hold
96
﹤0.01% 3153
2022
Q3
$32K Buy
96
+23
+32% +$8.33K ﹤0.01% 3219
2022
Q2
$24K Buy
73
+28
+62% +$9.82K ﹤0.01% 3415
2022
Q1
$20K Sell
45
-6
-12% -$2.46K ﹤0.01% 3586
2021
Q4
$23K Sell
51
-41
-45% -$20.6K ﹤0.01% 3492
2021
Q3
$52K Buy
92
+45
+96% +$22.6K ﹤0.01% 3052
2021
Q2
$24K Buy
47
+44
+1,467% +$27.9K ﹤0.01% 3399
2021
Q1
$2K Hold
3
﹤0.01% 3979
2020
Q4
$1K Sell
3
-5
-63% -$2.62K ﹤0.01% 3924
2020
Q3
$4K Hold
8
﹤0.01% 3730
2020
Q2
$5K Hold
8
﹤0.01% 3651
2020
Q1
$4K Sell
8
-26
-76% -$14.1K ﹤0.01% 3650
2019
Q4
$20K Hold
34
﹤0.01% 3321
2019
Q3
$22K Sell
34
-23
-40% -$19.1K ﹤0.01% 3309
2019
Q2
$44K Buy
57
+7
+14% +$4.92K ﹤0.01% 3004
2019
Q1
$36K Hold
50
﹤0.01% 3131
2018
Q4
$23K Hold
50
﹤0.01% 3251
2018
Q3
$43K Sell
50
-22
-31% -$15.9K ﹤0.01% 3088
2018
Q2
$49K Sell
72
-56
-44% -$28.5K ﹤0.01% 2992
2018
Q1
$56K Hold
128
﹤0.01% 2902
2017
Q4
$56K Hold
128
﹤0.01% 2896
2017
Q3
$64K Hold
128
﹤0.01% 2793
2017
Q2
$70K Buy
128
+28
+28% +$17.8K ﹤0.01% 2725
2017
Q1
$66K Buy
100
+93
+1,329% +$49.7K ﹤0.01% 2754
2016
Q4
$2K Buy
+7
New +$2.25K ﹤0.01% 3867

Other funds holding TVRD

PNC Financial Services Group's TVRD Position: Q1 2026 in Review

PNC Financial Services Group increased its Tvardi Therapeutics (TVRD) stake by 77% in Q1 2026, buying an estimated $882 and bringing the position to 519 shares worth $1.65K. The position accounts for ﹤0.01% of the portfolio, ranked #4639.

PNC Financial Services Group first reported a position in TVRD in Q4 2016 and has held it in 30 quarters since. The position peaked at $70K in Q2 2017. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • PNC Financial Services Group held 519 shares of Tvardi Therapeutics worth $1.65K as of Q1 2026.
  • PNC Financial Services Group bought 225 Tvardi Therapeutics shares in Q1 2026, an estimated $882.
  • Tvardi Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4639 holding.
  • PNC Financial Services Group first reported a position in Tvardi Therapeutics in Q4 2016 and has held it in 30 quarters since.
  • PNC Financial Services Group's Tvardi Therapeutics position peaked at $70K in Q2 2017.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.